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RESEARCH ARTICLE

Rasagiline effects on glucose metabolism, cognition, and tau in
Alzheimer’s dementia
Dawn C. Matthews1
Ana S. Lukic1

Aaron Ritter2

Carolyn Revta4

James B. Leverenz7
Jeffrey Cummings2,11

Ronald G. Thomas3

Jefferson W. Kinney5

Howard Fillit8

Kate Zhong9

Randolph D. Andrews1
Babak Tousi6

Howard H. Feldman10

1

ADM Diagnostics, Inc., Northbrook, Illinois, USA

2

Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, Nevada, USA

3

Department of Family Medicine and Public Health, UCSD, La Jolla, California, USA

4

Alzheimer’s Disease Cooperative Study, University of California San Diego School of Medicine, La Jolla, California, USA

5

Department of Brain Health, University of Nevada Las Vegas, Las Vegas, Nevada, USA

6

Neurologic Institute, Cleveland Clinic, Cleveland, Ohio, USA

7

Cleveland Clinic Lou Ruvo Center for Brain Health, Cleveland, Ohio, USA

8

Alzheimer’s Drug Discovery Foundation, New York, New York, USA

9

CNS Innovations, LLC, Henderson, Nevada, USA

10

Department of Neurosciences, Alzheimer’s Disease Cooperative Study, San Diego, University of California, La Jolla, California, USA

11

Department of Brain Health, Chambers-Grundy Center for Transformative Neuroscience, School of Integrated Health Sciences, University of Nevada Las Vegas,
Nevada, USA

Correspondence
Dawn C Matthews, ADM Diagnostics, Inc., 555
Skokie Blvd., Suite 500, Northbrook, IL 60062.
Email: dmatthews@admdx.com

Abstract
Background: A Phase II proof of concept (POC) randomized clinical trial was conducted to evaluate the effects of rasagiline, a monoamine oxidase B (MAO-B) inhibitor

Funding informationThis study was funded
by the Alzheimer’s Drug Discovery Foundation (ADDF). The ADDF did not influence the
study protocol, data analysis, interpretation of
results, or preparation of the article.

approved for Parkinson disease, in mild to moderate Alzheimer’s disease (AD). The
primary objective was to determine if 1 mg of rasagiline daily for 24 weeks is associated with improved regional brain metabolism (fluorodeoxyglucose–positron emission
tomography [FDG-PET]) compared to placebo. Secondary objectives included measurement of effects on tau PET and evaluation of directional consistency of clinical end
points.
Methods: This was a double-blind, parallel group, placebo-controlled, communitybased, three-site trial of 50 participants randomized 1:1 to receive oral rasagiline or
placebo (NCT02359552). FDG-PET was analyzed for the presence of an AD-like pattern as an inclusion criterion and as a longitudinal outcome using prespecified regions
of interest and voxel-based analyses. Tau PET was evaluated at baseline and longitudinally. Clinical outcomes were analyzed using an intention-to-treat (ITT) model.

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any
medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
© 2020 The Authors. Alzheimer’s & Dementia: Translational Research & Clinical Interventions published by Wiley Periodicals, Inc. on behalf of Alzheimer’s Association.
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Results: Fifty patients were randomized and 43 completed treatment. The study met
its primary end point, demonstrating favorable change in FDG-PET differences in
rasagiline versus placebo in middle frontal (P < 0.025), anterior cingulate (P < 0.041),
and striatal (P < 0.023) regions. Clinical measures showed benefit in quality of
life (P < 0.04). Digit Span, verbal fluency, and Neuropsychiatric Inventory (NPI)
showed non-significant directional favoring of rasagiline; no effects were observed in
Alzheimer’s Disease Assessment Scale-Cognitive Subscale (ADAS-cog) or activities of
daily living. Rasagiline was generally well tolerated with low rates of adverse events
and notably fewer neuropsychiatric symptoms in the active treatment group.
Discussion: These outcomes illustrate the potential benefits of rasagiline on clinical
and neuroimaging measures in patients with mild to moderate AD. Rasagiline appears
to affect neuronal activity in frontostriatal pathways, with associated clinical benefit potential warranting a more fully powered trial. This study illustrated the potential benefit of therapeutic repurposing and an experimental medicine proof-of-concept
design with biomarkers to characterize patient and detect treatment response.
KEYWORDS

Alzheimer’s disease, dopamine, FDG-PET, flortaucipir, glucose metabolism, MAO-B, QoL-AD,
rasagiline, tau PET

1

INTRODUCTION

cal progression in mild cognitive impairment patients.12,13 No trial has
examined the effects of rasagiline on functional brain networks and

The need for effective therapeutics for patients with mild to

relationship to clinical benefit. The present study sought to under-

moderate Alzheimer’s disease (AD) is urgent, given limitations of

stand the rasagiline as a potential treatment for patients with mild

currently approved medications and a high rate of negative clin-

to moderate AD, supported by imaging of neuronal function and tau

ical trial

outcomes.1

We conducted a Phase II “proof of concept”

pathology.

(POC) randomized clinical trial to evaluate the potential benefit

The primary end point was change in cerebral glucose metabolism

of rasagiline in patients with mild to moderate AD. Rasagiline is a

measured using fluoro-2-deoxyglucose (FDG) positron emission

selective monoamine oxidase B (MAO-B) inhibitor approved for

tomography (PET), demonstrated to correspond to disease progres-

treatment of Parkinson disease (PD) that has been shown to be

sion and functional treatment effects.14,15 Based on prior studies,16

safe and well-tolerated. MAO-B inhibition increases the availability

we hypothesized that FDG changes would be measurable with greater

of dopamine, which mediates cognitive functions including exec-

power over a shorter duration than clinical effects and could aid in

utive abilities, working memory, attention, and reward as well as

understanding the biological basis for potential clinical outcomes.

motor function.2 In nonclinical AD models, rasagiline has demon-

FDG-PET was also used to evaluate the presence of an AD-like pattern

strated potential neuroprotection, with reductions in amyloid

of glucose metabolism as an enrollment prerequisite, increasing

accumulation, tau hyperphosphorylation, and neurofibrillary tangle

confidence in a diagnosis of AD. A progressive pattern of temporopari-

formation.3,4

etal hypometabolism has been reported to differentiate AD from

Studies of rasagiline in patients with PD and schizophrenia sug-

other dementias, correlate with clinical status,17 and to be consistent

benefits.5–7

with brain amyloidopathy.18 Clinical end points were evaluated as

gest that the agent produces cognitive and other clinical

Selegiline, a related MAO-B inhibitor, has shown cognitive benefit in

secondary outcomes to verify directional consistency with FDG.

AD and PD,8–10 and phase II and III trials of the MAO-B inhibitor

This trial also included longitudinal measurement of tau with flor-

lazabemide in AD patients demonstrated benefit in several cogni-

taucipir (Tauvid; Avid Radiopharmaceuticals) as a measure of AD

tive and behavioral endpoints.11 However, some clinical studies of

pathology. Tau aggregation is observed early in AD in medial temporal

MAO-B inhibitors have shown mixed or negative results. For exam-

regions, spreading to lateral temporal, posterior, and frontal neocortex

ple, sembragiline did not meet cognitive or functional end points in

as AD progresses.19–21 Tau increases have been detected over periods

AD patients over 52 weeks, but neuropsychiatric and functional ben-

as short as 9 months.22 This trial expanded on prior studies by measur-

efit was noted in the more impaired subgroup. Ladostigil showed

ing tau changes over a shorter period of 24 weeks and a broad range of

potential atrophy-slowing effects but did not significantly alter clini-

AD severity, concurrent with FDG-PET.

3 of 12

MATTHEWS ET AL .

HIGHLIGHTS

RESEARCH IN CONTEXT

∙ Rasagiline is a monoamine oxidase B inhibitor approved in

1. Systematic review: The authors reviewed the literature

Parkinson disease.

using PubMed, meeting abstracts and presentations, and

∙ Rasagiline was evaluated in patients with mild to moderate

other on-line searches. Relevant publications regarding

Alzheimer’s disease.
∙ A beneficial effect on frontostriatal glucose metabolism

studies of monoamine oxidase B (MAO-B) inhibitors and
imaging biomarkers used in the study were cited.

was observed versus placebo.

2. Interpretation: This double-blind, placebo-controlled

∙ Directional changes in quality of life and cognition sup-

experimental medicine study of the effects of rasagiline

ported clinical benefit.
∙ Relationships were observed between tau, other biomark-

in Alzheimer’s disease (AD) met its primary outcome of
improved or mitigated decline of glucose metabolism
in the treatment group compared to placebo. Direc-

ers, and treatment effect.

tional changes consistent with treatment benefit were
observed in some measures of cognition, including those
mediated by frontal subcortical systems sensitive to

2

dopaminergic effects, and quality of life.

METHODS

3. Future Directions: Improved treatments for patients with

2.1

mild-to-moderate AD are needed. Repurposed agents

Study design

offer a means of developing new therapies while shortening development times and reducing cost. This study

This was a double-blinded, randomized, placebo-controlled study of

suggests that rasagiline warrants further evaluation as

the effects of 0.5 mg of rasagiline daily followed by 5 months of 1 mg of

a repurposed therapy for AD, and illustrates a proof-of-

oral rasagiline daily in 50 patients with mild to moderate AD (clinical-

concept (POC) study design as a model for other studies.

trials.gov NCT02359552). The study was conducted after institutional
review board approval with informed consent. Key inclusion criteria
were a clinical diagnosis of probable AD (National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer’s

Oral Word Association Test (COWAT), Alzheimer’s Disease Coopera-

Disease and Related Disorders Association (NINDS-ADRDA) criteria),

tive Study-Clinical Global Impression of Change (ADCS-CGIC), ADCS

age 50 to 90 years, Mini-Mental State Exam (MMSE) 12-26, and Flu-

Activities of Daily Living (ADL) scale, Quality of Life-AD (QoL-AD, with

orodeoxyglucose Positron Emission Tomography (FDG-PET) pattern

study partner), and Neuropsychiatric Inventory (NPI).

of hypometabolism consistent with AD.23 Exclusion factors included
neurologic, radiologic, or laboratory indications of non-AD dementia;
medications that might interact with rasagiline; and factors that might

2.2

Randomization

lead to inability to complete the study. Patients on stable doses of
cholinesterase inhibitors and memantine for at least 3 months prior to

The study was conducted by the Cleveland Clinic Lou Ruvo Center for

randomization were permitted. No dose changes were permitted dur-

Brain Health at three sites (Las Vegas NV, Cleveland OH, Lakewood

ing the study.

OH). Randomization was stratified by site, performed by the research

The primary outcome measure of this exploratory trial was the

pharmacist using a predetermined randomization schedule in which

change from baseline to week 24 in FDG-PET in pre-specified

participants were assigned to rasagiline or placebo in a 1:1 ratio using

AD-relevant regions including medial and lateral temporal, poste-

randomly generated blocks of four or six participants.

rior cingulate-precuneus, inferior parietal, and middle frontal cortices. The anterior cingulate and striatum, relatively preserved in
late AD, were prespecified given their glucose metabolic correlation with

dopamine24

2.3

Statistical power

and a reported increase in striatal glucose

metabolism with associated neuropsychiatric benefit following selegi-

Prior FDG-PET studies showed that metabolic changes associated

line administration.25 A voxel-based data-driven pattern derived from

with cognitive effects in AD can be detected in an unpaired design

a multivariate machine learning analysis of baseline and 24-week scans

with less than 20 participants per arm.14 Disease-related decline can

was evaluated. This approach measures multi-region response as a sin-

be detected, although powered measurement of mitigation requires

gle end point, taking into account relationships between regions.

additional participants or time.16 The study was not powered for

Secondary outcome measures included change in tau measured

clinical significance, but—as an experimental medicine approach—was

by flortaucipir PET over 24 weeks; safety and tolerability; and the

designed to assess directionality for consistency with FDG findings and

following clinical end points: Alzheimer’s Disease Assessment Scale–

to determine the number of participants required to show a rasagiline-

Cognitive Subscale (ADAS-cog), MMSE, Digit Span (DS), Controlled

placebo difference in a powered trial.
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F I G U R E 1 Baseline FDG and Tau burden. a-c, Tau burden for three participants age 61, 72, and 79 years shown with baseline clinical and FDG
scores. d, Pattern of hypometabolism and preservation relative to whole brain that is quantified by the AD Progression score. e, Relationship
between participant age and total tau SUVR. f, Relationship between tau burden in a composite of temporal and parietal regions involved in the
pattern of (d) versus FDG-AD Progression score

2.4

Procedures

amyloid negative and cognitively normal, amyloid positive with various
stages of MCI and AD, frontotemporal dementia, and dementia with

2.4.1

Medication

Lewy bodies (DLB). The second quantifies the degree to which a scan
expresses a pattern of hypometabolism and preservation relative to

Rasagiline was initiated at 0.5 mg once daily for 4 weeks, increased to

whole brain that reflects the progression of AD from amyloid negative,

a 1 mg dose once daily at week 5, and maintained at this dose until

cognitively normal status through amyloid-positive AD dementia. This

the end of week 24. Active and placebo tablets were provided by Teva,

pattern (Figure 1d) is characterized by hypometabolism in posterior

re-coated identically, and repackaged by randomization ID in a blinded

cingulate, precuneus, inferior parietal, and temporal cortices, and cor-

manner.

relates with subsequent rate of cognitive decline.23 Participants were
included if their highest probability class was on the AD spectrum, with
or without indication of secondary disease such as DLB.

2.4.2

Image acquisition and measurement

FDG Standardized Uptake Value ratios (SUVRs) were measured
and compared using different reference regions to confirm that

MRI was acquired at screening, and FDG and flortaucipir PET imag-

changes were not driven by a single reference. Data-driven multi-

ing were performed at baseline and at week 24. Images were acquired

variate machine learning was applied to identify voxel intensity pat-

using protocols based upon the Alzheimer’s Disease Neuroimaging Ini-

terns characterizing differences between treatment arms. Scans were

tiative (ADNI, www.adni-info.org) and processed as described in the

grouped into classes based upon visit (baseline, 24 weeks), study arm,

Supplemental Material.

and age (younger, older), and input to the classifier software. The

Each participant’s baseline FDG-PET scan was evaluated using two

software used Principal Component Analysis (PCA), Canonical Variate

previously developed image classifiers that use a single time point.

Analysis (mathematical combinations of PCs), and intensive iterative

The first was trained to differentiate scans of persons having status of

split-half data resampling to determine the pattern(s) that best discrim-
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inated groups while minimizing data overfitting.26 Pattern expression

was performed on the full data set, splitting the sample at the median

was quantified as a numeric score for each participant.

for the MMSE (score of 20). Pre-defined exploratory analyses eval-

Tau SUVRs were measured in cortical tissue excluding cerebellum;
a composite temporal region, the regions measured for FDG-PET; and

uated treatment effects for all clinical end points by baseline clinical
severity measured by MMSE.

using an adaptive approach that measured the change in subjectspecific set of voxels that were suprathreshold at baseline or 24 weeks
to avoid directional bias, standardized to a common total volume.

3

RESULTS

White matter and cerebellar cortex reference regions were defined
using a Gaussian decomposition approach (PERSI) (Supplement).27

3.1

Participants

Between May 19, 2015 and January 26, 2018, 96 participants were

2.4.3

Clinical end points

screened, of whom 50 were randomized to rasagiline or placebo and
43 completed treatment. Of the 25 placebo participants, 3 were lost

The ADAS-cog, NPI, ADCS-ADL, DS, and COWAT were administered

to follow-up (delusions, stroke, worsening pseudobulbar/other effects),

at baseline, and at weeks 4, 8, 24, and 28. MMSE was administered

and one did not have a week-24 FDG PET scan, resulting in 21 placebo

at screening, baseline, and 24 weeks. The CGIC was collected at

participants for image analysis. Of the 25 participants in the rasagiline

4, 8, 24, and 28 weeks. QoL-AD was administered at baseline and

arm, 4 were lost to follow-up (broken hip/rib, atrial fibrillation, other

24 weeks. Safety was monitored through weekly review of adverse

non-adverse event factors) (Figure S1).

events throughout the study.

Table 1 shows the demographic and baseline clinical characteristics
of enrolled patients by treatment arm. Age, sex, education, genotype,
and baseline NPI, DSPAN, and COWAT scores did not differ between

2.4.4

Statistical analysis

groups. MMSE and ADAS-cog baseline scores were more impaired (by
chance) in the placebo arm than the rasagiline arm (P < 0.06), whereas

Participants who completed both PET visits and passed image quality

the rasagiline arm had worse baseline QoL-AD scores (P < 0.02). Of

control were evaluated longitudinally. Six-month changes in SUVR val-

the 43 participants who completed the study, one did not have a

ues and classifier scores were compared between treatment arms by

week-24 FDG PET scan and 3 were excluded from analysis due to

ANOVA adjusted for age, baseline values, and interaction terms when

pre-specified behavioral or motion confounds during image acquisi-

applicable (JMP v14 (SAS); G:Power software). Comparisons were also

tion. Among the 39 participants included in longitudinal image anal-

made within younger and older age strata given reports of greater tau

ysis, baseline MMSE and ADAS-cog scores did not differ between

and more rapid progression in younger AD participants20 and potential

groups and QoL-AD scores were worse in the rasagiline-treated group

comorbidities that may influence outcomes in older participants. Sta-

(P < 0.05).

tistical comparisons were based on absolute change values.
Mixed-model repeated-measures analyses were used to assess
between-group clinical end point differences in modeled change over

3.2

Baseline PET and ApoE characterization

24 weeks. The dependent variable was the change from baseline score.
Fixed effects were baseline outcome measure scores, treatment arm,

Of the 59 participants whose screening FDG scans were analyzed using

visit, and treatment-by-visit interaction. Study visit was treated as

the Dementia Classifier, 57 exhibited a pattern of hypometabolism

a continuous variable; an unstructured variance–covariance matrix

classified as AD-like and were included for potential enrollment.

was used. The primary efficacy analysis was based on the modified

Seventy-one percent of participants were apolipoprotein E gene

intention-to-treat (mITT) population, including all randomly assigned

(APOE) ε4 variant carriers, consistent with trials where positive amy-

participants with at least one post-baseline observation. Testing for

loid imaging is used as an entry criterion.29 Participants were diverse

treatment differences was conducted by assessing the statistical signif-

in FDG AD Progression Classifier scores (Figure 1f), which correlated

icance of the treatment-by-visit regression coefficient. Relationships

with baseline MMSE (R = -0.44, P < 0.001) and ADAS-cog scores

between clinical and imaging end points were explored using correla-

(R = 0.42, P < 0.003). AD Progression score and baseline MMSE did not

tion (Pearson R). Because this was a preliminary POC study, no adjust-

differ significantly between study arms in the PET analysis population.

ments for multiple comparisons were made and a two-sided P-value of
0.05 was considered significant.

Tau burden varied widely across participants (Figures 1a-c) but did
not differ between treatment arms. Tau was associated with age (Fig-

In addition to including baseline values as model covariates,

ure 1e), as younger participants (age 57 to 69 years) exhibited perva-

methods were implemented to further assess the impact of baseline

sive burden while oldest participants (late 70s to 90) had lower, pri-

differences on outcomes. The software package “designmatch”28 was

marily temporal burden with smaller posterior clusters, and patients in

used to match treatment and placebo groups for MMSE, ADL, ADAS,

their 70s showed a wide range. Spatial patterns varied in asymmetry

and QoL-AD at baseline. T-test and Analyses of Covariance (ANCO-

and occipital involvement. Forty-seven of the 50 participants (94%) had

VAs) were run on the reduced set. A Cochran-Mantel-Haenszel test

readily visualized elevated flortaucipir and positive regional SUVRs,
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TA B L E 1

Baseline demographic and clinical characteristics of the study population

Mean (std dev)

Placebo (N = 25)

Rasagiline (N = 25)

All (N = 50)

P-value (Placebo vs Rasagiline)

Age (range)

73.4 (7.1)
(57 - 84)

74.7 (7.4)
(62 - 90)

74 (7.2)
(57 - 90)

0.53

Gender (F/M)%

44 / 56

56 / 44

50 / 50

0.60

Education

14 (2)

14 (3

14 (3)

0.83

ADAS-Cog

28 (11)

23 (6)

26 (9)

0.06

MMSE

19 (5)

21 (4)

20 (4)

0.06

ADL

58 (11)

62 (8)

60 (10)

0.20

NPI

8 (9)

8 (8)

8 (8)

0.78

DSPAN

12 (3)

13 (3)

12 (3)

0.13

COWAT

21 (13)

27 (13)

24 (13)

0.13

QOL-AD

40 (5)

36 (6)

38 (6)

0.02

APOE 2/3

4%

4%

4%

0.50

2/4

0%

4%

2%

3/3

16%

29%

22%

3/4

60%

38%

49%

4/4

20%

25%

22%

AChEI(s)

84%

84%

84%

1.00

Memantine

44%

40%

42%

0.78

Antidepressant(s)

36%

56%

46%

0.16

Anxiolytic(s)

4%

4%

4%

1.00

Antipsychotic(s)

8%

4%

6%

0.56

site id 1

48%

52%

50%

1.00

site id 2

36%

36%

36%

site id 3

16%

12%

14%

while three had threshold cortical SUVR values (1.3). Total tau corre-

Placebo arm FDG AD Progression scores increased in sever-

lated with FDG AD Progression classifier score (R = −0.41, P < 0.003).

ity (P < 0.01), and regional SUVRs likewise decreased in posterior
cingulate-precuneus (P < 0.03, E.S. 0.74), inferior parietal (P < 0.01,
E.S. 0.86), and middle frontal (P < 0.001, E.S. 1.74) regions, with decline

3.3
3.3.1

Trial outcomes

greater in younger participants.

Primary end point
3.3.2

Secondary end points

The study met its primary end point of improvement in longitudinal
glucose metabolism in rasagiline-treated participants versus placebo

Longitudinal clinical end points for the rasagiline and placebo arms

in one or more prespecified regions and in the pattern determined

over 24 weeks are presented in Figure 3. A favorable outcome for

through voxel-based analysis (Figure 2a,b). Rasagiline-treated par-

rasagiline compared to placebo was observed for QoL-AD (P < 0.04 all

ticipants decreased less than placebo-treated participants in middle

participants, adjusted for baseline QoL; P < 0.07 with a reduced set

frontal cortex (left P < 0.012, E.S. 0.82; bilateral P < 0.025, E.S. 0.75),

of matched baseline participants and adjusted for baseline QoL and

anterior cingulate cortex (P < 0.043, E.S. 0.68), striatum (P < 0.02,

MMSE; P < 0.07 Mantel-Haenszel chi-square). In particular, uniform

E.S. 0.83) (Table 2) and in the voxel-based classifier-derived pattern

improvements were observed in rasagiline-treated participants com-

(P < 0.02, Figure 2b), which was consistent with regional effects. Treat-

pared to decline in placebo participants with similar baseline values

ment effects remained significant when including age, baseline SUVR,

(Figure 3b,c), and trajectories were clearly separated in the matched

and baseline MMSE as covariates. Age was a significant covariate for

baseline analysis of all ages (Figure 3d). Directionally favorable out-

middle frontal cortex and striatum. Results using whole brain, subcor-

comes were observed in Digit Span, CGIC, COWAT, and NPI. No sig-

tical white matter, and pons as alternate reference regions were in

nificant differences were observed in ADL and ADAS-cog (Figure 3a,

agreement regarding affected regions and directionality.

Table S1). Mean values for each time point and results for pre-specified
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F I G U R E 2 a, Twenty-four-week change in FDG SUVR in placebo- versus rasagiline-treated patients. b, Longitudinal voxel-based classifier
results showing regions where rasagiline-treated participants declined less in glucose metabolism than placebo-treated participants

MMSE strata are shown in the Supplementary Material. There were no

in anterior cingulate, frontal, and striatal regions (Figure S2b,c) and

side effects.

with FDG SUVR increases in these regions (anterior cingulate R = 0.47,

Increases in tau PET were observed in some participants over

P < 0.002, caudate R = 0.47, P < 0.002) (Figure S2d).

24 weeks, particularly those with higher baseline values (Figure 4a,b).
Greater slopes and statistical power were observed when using the
adaptive method that defined the region of interest according to com-

3.3.4

Safety and tolerability

bined pre- or post-suprathreshold voxels (Figure 4b). No treatment differences in change in flortaucipir were observed in cortical regions hav-

Rasagiline was generally well tolerated, with neuropsychiatric adverse

ing suprathreshold values at baseline. Uniform longitudinal decreases

events (AEs) in 5 (20%) placebo and 0 (0%) rasagiline patients, non-

were observed in the rasagiline but not placebo arm in subcortical

neuropsychiatric AEs in 10 (40%) placebo and 13 (52%) rasagiline

regions, particularly accumbens (P < 0.0001) and putamen (P < 0.003)

patients, and no treatment-related deaths (Table S2). No rasagiline-

(Supplement).

treated participants experienced neuropsychiatric symptoms of agitation/irritability or psychosis compared to five placebo participants
(t test not significant).

3.3.3
Relationships between imaging and clinical
end points
4

DISCUSSION

Higher tau burden, lower glucose metabolism, and lower cortical thickness in temporal regions at baseline correlated with greater decline in

4.1

Rasagiline effects

MMSE score in placebo participants (P < 0.008, P < 0.05, P < 0.004,
respectively). These relationships (Figure S2a) were not seen in rasag-

This investigation of rasagiline as a treatment for AD met its pri-

iline trajectories, which were relatively stable or improved indepen-

mary outcome of demonstrating improvements or less decline in glu-

dent of these baseline values. Longitudinal differences between rasag-

cose metabolism changes in prespecified regions compared to placebo

iline and placebo arms were most pronounced in participants having

over 24 weeks. FDG-PET findings suggested that rasagiline supports

greater tau, lower metabolism, and lower volumes in temporal regions

metabolic function in frontostriatal networks. Rasagiline prolongs

at baseline. Change in QoL-AD score, which differed between placebo

dopamine availability through MAO-B inhibition, and results were

and rasagiline arms, correlated with a pattern of increased metabolism

consistent with previous studies that have established dopaminergic
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in each arm of the present study were taking acetylcholinesterase
inhibitors and/or medications such as memantine, rasagiline effects
were incremental to the action of these medications.
The favorable effect in QoL observed for rasagiline was consistent

n.s.

0.9% (−1.5–3.3%)
0.2% (−1.5–1.9%)

memory and other cognitive function.30,31 Because84% of participants

with benefits on QoL reported with rasagiline in PD patients.5,6 QoL
has been associated in other studies with dopaminergic function.31
Changes in DS, CGIC, COWAT, and NPI were directionally consistent
with FDG results. The lack of ADAS-cog effect was similar to some
studies of MAO-B inhibitors and rotigotine,32 illustrating that a POC

n.s.

(3.5%)
(3.1%)

−1.6%

(3.5%)
(3.1%)

−2.0%

−2.2%

−2.6%

−0.001 (−0.01–0.01) 0.007 (−0.01–0.02)

−0.018 (0.022)

−0.025 (0.029)
−0.017 (0.023)

−0.016 (0.018)

Post cing - precuneus Inferior parietal

effects on frontostriatal neuronal function, with benefits on working

approach may efficiently identify end points for larger trials relevant

0.6% (−1.8–3.0%)

chiatric events compared to the placebo group suggests an additional
effect worthy of further study. This observation supports the finding of
a potential MAO-B inhibition effect on neuropsychiatric symptoms in
n.s.

(4.4%)

(4.4%)

−2.1%

−2.7%

0.005 (−0.01–0.02)
0.005 (−0.02–0.03)

−0.020 (0.029)

−0.016 (0.024)
−0.010 (0.034)

Lateral temporal

rasagiline-treated participants who spontaneously reported neuropsy-

AD patients reported in a phase 2 trial of sembragiline.12

0.8% (−2.4-4.0%)

treatment may be most detectable in participants exceeding baseline
thresholds of temporal tau burden, hypometabolism, and atrophy (Figure S2). Prospective biomarker stratification may help focus analyses
on subgroups in which benefit is greatest.
n.s.

(5.7%)

(5.7%)

−1.8%

−2.5%

−0.015 (0.034)

Medial temporal

Our findings indicate that differences associated with rasagiline

The longitudinal progression in AD classifier pattern in placebo

based on the SUVR values and comparison of differences from baseline. Abbreviation: ns, not significant.
a

2.4% (0.2-4.3%)

0.023
0.054

1.6% (0.0-3.2%)
2.2% (0.1-4.3%)

0.041
0.025

2.5% (0.3-4.7%)
Difference (95% CI)

triatal regions were similar to the magnitude of change observed in

P-valuesa

(3.1%)
(2.1%)
(3.1%)
(3.5%)

−0.2%

(3.1%)
(2.7%)

−0.4%
−0.6%

(3.1%)
(3.5%)

−1.0%
Rasagiline

−2.6%
−2.0%
−2.8%
−3.5%
Placebo

Percentages

−0.024 (0.029)

0.013 (0.00–0.04) 0.022 (0.00–0.04)
0.016 (−0.00–0.03)
0.020 (0.00–0.04)
Difference (95% CI)

−0.003 (0.018)

−0.016 (0.022)
−0.020 (0.021)

−0.003 (0.026)
−0.011 (0.030)

−0.032 (0.030)
Placebo

Rasagiline

Striatum
Superior frontal
Anterior cingulate
Middle frontal

−0.002 (0.028)

group and the 2% to 3% differences between study arms in frontos-

SUVRs

TA B L E 2

Region of interest results: difference (24 weeks minus baseline) mean, S.D. and difference between arms with 95% confidence interval

to the cognitive signature of the treatment. The lower number of

other FDG-PET studies of AD and central nervous system drugs.14,15
The placebo group decreases in striatum, which is relatively preserved
in late-onset AD, was driven by decreases in left caudate in younger
patients. Caudate glucose metabolism has been identified as significantly reduced in early onset versus Late-onset AD.33

4.2

Tau

This study illustrated the diverse distribution of tau in AD as well as its
relationships to age, FDG-PET, and clinical status. Results suggest that
tau accumulation is observable over periods as short as 24 weeks, with
higher accumulation rates associated with higher baseline tau burden.
Adaptive region definition increased change detection likely because
it captured the diverse spatial distribution of tau across participants
without diluting to entire cortex, and may minimize impact of head
motion–induced tissue shifts by “ORing” pre- and post-suprathreshold
boundaries.
Because rasagiline is a highly selective MAO-B inhibitor, this study
provided a stringent test of possible MAO-B binding of flortaucipir. The
uniform flortaucipir signal reductions observed in subcortical regions
in rasagiline-treated but not placebo-treated participants may suggest
binding to MAO-B. However, effects were very weak compared to
MAO-B-binding reductions caused by a rasagiline dose equal to that
in the present study34 and to the signal depletion of [18F]THK5351,
a tracer with strong MAO-B affinity, following rasagiline treatment35
(further discussion in Supplement).
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F I G U R E 3 a, Longitudinal change in clinical end points by study arm. b, Individual participant longitudinal QoL-AD scores in the Younger
subgroup. c, Change in QoL by study arm, younger, and older subgroups (PL = placebo, RAS = rasagiline treated). d, Change in QoL-AD from
baseline in placebo and rasagiline group after matching for baseline clinical characteristics; decreases reflect worsening and increases represent
improvement

4.3

Study limitations

balance these variables all supported the baseline-adjusted model
results. However, imbalances impact analysis complexity and inter-

Limitations of the study include its small sample size and 24-week dura-

pretation, and prospective approaches to balancing arms could aid in

tion, intended for POC. The lack of amyloid measurement was a diag-

other trials.

nostic limitation. However, flortaucipir, selective for AD variant tau,
provided evidence of AD pathology and may serve as a surrogate indicator of amyloid given the observed relationship between neocortical

4.4

Conclusion

tau and positive amyloid burden.36,37 The high number of APOE ε4 carriers (71%) in the study is consistent with a trial population comprised

The findings of a favorable effect of rasagiline on longitudinal FDG over

primarily of AD patients.

24 weeks of treatment and directional benefit on clinical outcomes

The by-chance imbalance in baseline MMSE, ADAS-cog, and QoL

support a potential benefit of rasagiline for AD patients. Given that

scores between treatment arms posed a challenge also seen in other

this is an available, generic treatment with substantial safety data, it

studies.38,39

would be a cost- and time-effective addition to available treatments. A

The multiple approaches applied to adjust for and/or
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F I G U R E 4 a, Example of increases in tau burden in a high tau imaging participant over 24 weeks. b, Twenty-four-week changes in flortaucipir
SUVRs for middle frontal, posterior cingulate-precuneus, and an adaptive region determined by baseline and week 24 suprathreshold voxels, by
study arm
powered clinical trial with assessment of QoL-AD, executive function,
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